Novel Therapeutic Approaches in Metastatic Lung Adenocarcinoma

EP. 1: Molecular Testing for NSCLC in 2017

February 20th 2017

EP. 2: EGFR Testing for NSCLC

February 20th 2017

EP. 3: Treatment for EGFR+ NSCLC

February 20th 2017

EP. 4: Addition of Bevacizumab to Up-front therapy for EGFR+ NSCLC

February 20th 2017

EP. 5: Relapsed or Refractory EGFR+ NSCLC

February 20th 2017

EP. 6: Osimertinib for EGFR T790M Resistance Mutations in NSCLC

February 20th 2017

EP. 7: Upfront Use of Osimertinib in EGFR+ NSCLC

February 20th 2017

EP. 8: Progression of ALK+ NSCLC

February 20th 2017

EP. 9: Upfront Use of Next-Generation ALK Inhibitors in NSCLC

February 20th 2017

EP. 10: Third-Generation ALK Inhibitors for NSCLC

February 20th 2017

EP. 11: Upfront Use of Immunotherapy for NCSLC

February 20th 2017

EP. 12: PD-L1 Testing for NSCLC

February 20th 2017

EP. 13: New Data for Checkpoint Inhibitors in NSCLC

February 20th 2017

EP. 14: What to Do After Progression on Immunotherapy and for Non-Driver NSCLC

February 20th 2017